Tuesday, August 19, 2014
PropThink Readers Profit from Amicus Therapeutics Buy Recommendation
Premium readers over at PropThink.com are already up 15% since our buy recommendation was issued on Amicus Therapeutics [FOLD] on August 7 at $4.00 per share.
Though the investment premise remains intact, investors might want to either lock in existing short-term gains, or buy September 5 calls as downside insurance against any near-term clinical surprises.
Albeit the investment thesis is focused on monotherapy use of its proprietary, pharmacological chaperone migalastat in Fabry Disease, there are value-creating assets that should become more visible in late 2015. In the treatment of Pompe disease (a glycogen storage disorder caused by deficiency of an enzyme called acid α-glucosidase), Amicus is looking to leverage its proprietary Chaperone-Advanced Replacement Therapy platform to improve currently marketed ERTs through co-administration of a pharmacological chaperone prior to ERT infusion, and/ or to develop next-generation ERTs that consist of a proprietary lysosomal enzyme therapy co-formulated with a pharmacological chaperone.
Those investors looking for additional insight into our thoughts on FOLD and visible catalysts, such as Study 012, might consider opening their wallets and purchasing a subscription to PropThink.com.
Read more at PropThink: COMING UP: MAKE OR BREAK FOR AMICUS’ PHARMACOLOGICAL CHAPERONE TECHNOLOGY
Editor David J Phillips no longer holds a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.